Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
 
Status In progress
Process STA 2018
ID number 3848

Provisional Schedule

Committee meeting: 1 09 June 2022
Committee meeting: 1 09 June 2022
Expected publication 17 August 2022

Project Team

Project lead Daniel Davies

Email enquiries

Consultees

Companies sponsors AbbVie (upadacitinib)
Others Department of Health and Social Care
  NHS Bath and North Somerset CCG
  NHS England
  NHS Fylde & Wyre CCG
  Welsh Government
Patient carer groups Action on Pain
  Arthritis Action
  Arthritis and Musculoskeletal Alliance
  Back Care
  National Ankylosing Spondylitis Society Pain Concern
  Pain Relief Foundation
  Pain UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Versus Arthritis
Professional groups British Geriatrics Society
  British Institute of Musculoskeletal Medicine
  British Myology Society
  British Orthopaedic Association
  British Pain Society
  British Society for Paediatric and Adolescent Rheumatology
  British Society of Rehabilitation Medicine
  British Society for Rheumatology
  Chartered Society for Physiotherapy
  Primary Care Rheumatology & Musculoskeletal Medicine Society
  Physiotherapy Pain Association
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Occupational Therapists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Society of Medicine
  Society for Endocrinology
  UK Clinical Pharmacy Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Abbvie (adalimumab)
  Amgen (adalimumab)
  Biogen Biosimilars (adalimumab, etanercept, infliximab)
  Cellltrion Healthcare (infliximab)
  Eli Lilly (ixekizumab)
  Freseniunsius Kabi (adalimumab)
  Merck Sharpe and Dohme (golimumab, infliximab)
  Novartis (secukinumab)
  Pfizer (etanercept, infliximab)
  Sandoz (adalimumab, etanercept, infliximab)
  UCB Pharma (certolizumab pegol)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Bone Research Society
  Chronic Pain Policy Coalition
  Cochrane Musculoskeletal Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  Orthopaedic Research UK
  Pain Relief Foundation
  Society for Back Pain Research

Timeline

Key events during the development of the guidance:

Date Update
01 October 2021 We recently contacted all stakeholders for the appraisal of upadacitinib for treating active ankylosing spondylitis regarding a delay to this topic for operational reasons. Upadacitinib for treating active ankylosing spondylitis has now been rescheduled into the work programme. The appraisal is due to start late September 2021 and will be discussed at committee in early June 2022. This appraisal will now follow the Single Technology Appraisal Process and will not be included in a Multiple Technology Appraisal with Tofacitinib for treating active ankylosing spondylitis [ID3865] as originally advised. The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.
30 September 2021 Invitation to participate
30 September 2021 Invitation to participate
30 September 2021 In progress. rescheduled into the TA program
17 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
09 June 2021 Committee meeting: 1
22 January 2021 - 19 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance